Loading...
•
Sep 30, 2022
Organon Q3 2022 Earnings Report
Organon's existing portfolio delivered sustainable growth, with newly-acquired assets gaining traction.
Key Takeaways
Organon reported a 4% decrease in total net revenues as-reported, but a 3% increase excluding the impact of foreign currency. Women's Health grew 19% as-reported and 23% ex-FX. Net income from continuing operations was $227 million, or $0.89 per diluted share. Non-GAAP Adjusted net income from continuing operations was $337 million, or $1.32 per diluted share.
Total net revenues were $1,537 million, a decrease of 4% as-reported, but an increase of 3% ex-FX.
Women’s Health grew 19% as-reported, and 23% ex-FX.
Gross margin was 64.2% as-reported, compared with 61.9% in the prior year period.
Adjusted EBITDA margin was 35.5% compared with 38.2% in the third quarter of 2021.
Forward Guidance
Organon is updating its 2022 financial guidance ranges previously provided on August 4, 2022. The company's financial guidance does not assume an estimate for future IPR&D and milestone payments for business development transactions not yet executed.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...